Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725578 | 0.87 | FABP6 (0.66) | FABP6ABL1ALDH1A1MASP2MEN1 | |
| SCHEMBL22121440 | 0.85 | FABP6 (0.51) | FABP6ABL1ALDH1A1MASP2MEN1 | |
| SCHEMBL1870891 | 0.85 | FABP6 (0.55) | FABP6ABL1ALDH1A1MASP2MEN1 | |
| SCHEMBL3607728 | 0.84 | FABP6 (0.48) | FABP6ABL1ALDH1A1MASP2MEN1 | |
| Hydrochloric Acid SCHEMBL4682527 | 0.83 | FABP6 (0.54) | FABP6ABL1ALDH1A1MASP2MEN1 | |
| SCHEMBL14601528 | 0.83 | NPBWR1 (0.48) | ALDH1A1MEN1KMT2AKIF11MAPT | |
| SCHEMBL17747823 | 0.83 | FABP6 (0.47) | FABP6ABL1ALDH1A1MASP2MEN1 | |
| SCHEMBL4404802 | 0.83 | FABP6 (0.47) | FABP6ABL1ALDH1A1MASP2MEN1 | |
| SCHEMBL1202574 | 0.83 | KDM4E (0.50) | FABP6ABL1ALDH1A1MEN1KMT2A | |
| Bromide SCHEMBL214290 | 0.81 | KDM4E (0.49) | FABP6ABL1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118451062-A | Preparation and use of quinazolinediones | 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) | 2024-08-06 | — | — | CN | claimed |
| EP-4452952-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2024-10-30 | — | — | EP | disclosed |
| CN-118451062-A | Preparation and use of quinazolinediones | 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) | 2024-08-06 | — | — | CN | disclosed |
| WO-2023119320-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023119320-A1 | A PREPARATION OF QUINAZOLINEDIONES AND USE THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2023-06-29 | — | — | WO | disclosed |
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| US-8646616-B2 | Composite membrane with coating comprising polyalkylene oxide and imidazol compounds | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130136782-A1 | Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-05-30 | — | — | US | disclosed |
| WO-2011149572-A1 | POLYAMIDE MEMBRANE WITH COATING COMPRISING POLYALKYLENE OXIDE AND IMIDAZOL COMPOUNDS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110284454-A1 | COMPOSITE MEMBRANE WITH COATING COMPRISING POLYALKYLENE OXIDE AND IMIDAZOL COMPOUNDS | DOW GLOBAL TECHNOLOGIES LLC | 2011-11-24 | — | — | US | disclosed |
| US-4167569-A | ANTICOAGULANTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136782-A1 | Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives | FLNB, BRI3BP, CCNI | FABP6 2758/4885ABL1 446/4885ALDH1A1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.